Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24‐week, prospective, randomized, placebo‐controlled pilot trial

AIMS: To investigate the potential synergistic effects of combined exenatide (EXE) and dapagliflozin (DAPA) versus (PLAC) placebo and DAPA on hepatocellular lipid (HCL) reduction after 24 weeks of treatment. MATERIALS AND METHODS: Thirty patients with type 2 diabetes were randomized to weekly EXE an...

Descripción completa

Detalles Bibliográficos
Autores principales: Harreiter, Jürgen, Just, Ivica, Leutner, Michael, Bastian, Magdalena, Brath, Helmut, Schelkshorn, Christian, Klepochova, Radka, Krššák, Martin, Kautzky‐Willer, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247845/
https://www.ncbi.nlm.nih.gov/pubmed/33464703
http://dx.doi.org/10.1111/dom.14319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247845/
https://www.ncbi.nlm.nih.gov/pubmed/33464703
http://dx.doi.org/10.1111/dom.14319

Ejemplares similares